Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2010
At a glance
- Drugs Necitumumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ImClone Systems
- 08 Dec 2008 New trial record.